SCHEMBL6070728

SCHEMBL6070728

CC(C)CC(=O)Nc1ccc2[nH]c3c(c2c1)CCCC3=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.57
ALDH1A1 P00352 7/20 0.56
LMNA P02545 6/20 0.56
POLB P06746 1/20 0.56
RORC P51449 1/20 0.54
HPGD P15428 4/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 4/20 0.50
ALOX15 P16050 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071115 0.83 KDM4E (0.61) KDM4EALDH1A1LMNAPOLBHPGD
SCHEMBL5582972 0.83 MAPK10 (0.52) KDM4EALDH1A1LMNARORCHPGD
SCHEMBL6449516 0.82 P2RY12 (0.54) KDM4EALDH1A1LMNAPOLBHPGD
SCHEMBL6070281 0.79 RAB9A (0.45) KDM4EALDH1A1LMNAPOLBRORC
SCHEMBL6070286 0.79 RAB9A (0.45) KDM4EALDH1A1LMNAPOLBRORC
SCHEMBL6070799 0.78 MAPK10 (0.56) KDM4EALDH1A1LMNARORCHPGD
SCHEMBL6071247 0.76 KDM4E (0.58) KDM4EALDH1A1LMNAPOLBHPGD
SCHEMBL6071548 0.74 MAPK10 (0.49) KDM4EALDH1A1LMNARORCSMN1; SMN2
SCHEMBL3863733 0.72 MAPT (0.56) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL6070647 0.72 KDM4E (0.72) KDM4EALDH1A1LMNAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 KDM4E 1799/4885ALDH1A1 4446/4885LMNA 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.